About this trial
Immunotherapy have revolutionized the field of oncology, but response rates are low and all patients relapse, due to immunologic (myeloid immunosuppressive cells) and non-immunologic (cancer stem- cells (CSC)) mechanisms. CSC are able to circulate within blood, protected from destruction by immunosuppressive cells such as MDSC. Some factors such as G-CSF, administered to lower febrile neutropenia, should modulate properties of MDSC and CSC, but data are contradictory, and literature remain poor regarding its effects on the interactions between MDSC and CSC in blood clusters. Indeed, this project aims at better characterizing the effect of G-CSF on these interactions and on their functions in NSCLC patients receiving G-CSF.
Eligibility criteria
Qualifiers
Patients (male or female) aged ≥ 18 years
Histological or cytological proven lung adenocarcinoma, metastatic or locally advanced not accessible to local therapy
Receiving chemotherapy and immunotherapy as first-line treatment
Signed written informed consent (no later than the day of inclusion, and before the blood sample collection)
Disqualifiers
Patient with a small cell lung carcinoma
Non-metastatic disease
Actionable mutation or genomic alteration in EGFR, ALK or ROS1
Corticosteroids > 10 mg/j
Trial design
Treatments tested in this trial
- Blood sample